Negro F, Giostra E, Krawczynski K, Quadri R, Rubbia-Brandt L, Mentha G, Colucci G, Perrin L, Hadengue A
Division of Gastroenterology and Hepatology, University Hospital, Geneva, Switzerland.
J Hepatol. 1998 Jul;29(1):1-11. doi: 10.1016/s0168-8278(98)80172-4.
BACKGROUND/AIMS: Although the hepatitis C virus infection recurs in virtually all patients after liver transplantation, up to 50% of patients may not have histological recurrent hepatitis 1 year after liver transplantation. To study the relationship between hepatitis C virus infection and liver disease after liver transplantation, we compared the intrahepatic hepatitis C virus replication levels with the liver histopathology among liver transplant recipients.
The intrahepatic negative-strand HCV RNA (i.e. the putative hepatitis C virus replication intermediate RNA) was evaluated by a semi-quantitative, strand-specific reverse transcriptase-polymerase chain reaction in 44 liver specimens from 23 patients with hepatitis C virus reinfection after liver transplantation. Results were compared with the time from liver transplantation, presence, grading and staging of the recurrent hepatitis, amount of hepatitis C virus antigens in the liver and serum HCV RNA levels.
Negative-strand HCV RNA was detected in 42 liver specimens as early as 7 days after liver transplantation. Its titers correlated with the amount of intrahepatic hepatitis C virus antigens, but not with HCV RNA levels in serum. Levels of negative-strand HCV RNA in 19 specimens without hepatitis were comparable to those seen in 25 specimens with hepatitis (p=0.492), and were unrelated to the liver disease grading and staging scores. The intrahepatic hepatitis C virus replication could occasionally precede the recurrence of the hepatitis by several months.
Molecular evidence has been obtained for intrahepatic hepatitis C virus replication occurring early after liver transplantation. The level of replication is not correlated with the development of recurrent hepatitis, suggesting that hepatitis C virus may replicate without inducing morphological evidence of liver damage.
背景/目的:尽管肝移植术后几乎所有患者都会出现丙型肝炎病毒感染复发,但高达50%的患者在肝移植术后1年可能没有组织学上的复发性肝炎。为了研究肝移植后丙型肝炎病毒感染与肝脏疾病之间的关系,我们比较了肝移植受者肝内丙型肝炎病毒复制水平与肝脏组织病理学情况。
采用半定量、链特异性逆转录聚合酶链反应对23例肝移植后丙型肝炎病毒再感染患者的44份肝脏标本中的肝内负链HCV RNA(即假定的丙型肝炎病毒复制中间RNA)进行评估。将结果与肝移植后的时间、复发性肝炎的存在、分级和分期、肝脏中丙型肝炎病毒抗原的数量以及血清HCV RNA水平进行比较。
早在肝移植后7天,就在42份肝脏标本中检测到了负链HCV RNA。其滴度与肝内丙型肝炎病毒抗原的数量相关,但与血清中的HCV RNA水平无关。19份无肝炎的标本中的负链HCV RNA水平与25份有肝炎的标本中的水平相当(p = 0.492),且与肝脏疾病分级和分期评分无关。肝内丙型肝炎病毒复制偶尔可在肝炎复发前数月出现。
已获得肝移植后早期肝内丙型肝炎病毒复制的分子证据。复制水平与复发性肝炎的发展无关,这表明丙型肝炎病毒可能在不引起肝脏损伤形态学证据的情况下进行复制。